Tecvayli launch date?

Tecvayli is teclistamab-cqyv, a BCMA/CD3 bispecific antibody for multiple myeloma. In the United States, it was approved by the FDA in October 2022 and launched commercially there later in 2022. Approval and launch dates vary by country, with EU approval following in 2023.

If you’d like the exact date for a specific country or region, tell me which one and I’ll provide the precise date.